Celebrating 20 Years
And What’s Next in the
Scroll to Start Your Experience
Revolutions are born from the aspirations of people who believe there’s a better way.
Harnessing a breakthrough discovery in biology to treat disease in a better way, and transform the lives of patients in doing so, has been the mission for Alnylam from day one. Our founders believed that a new approach, leveraging small interfering RNA (siRNA) and the body's natural process for gene regulation - called RNA interference (RNAi), could be used to treat patients in ways that other classes of medicines - such as small molecules and antibodies - could not. They also believed that the unique characteristics of RNAi opened up a broader range of disease targets, including many which had been deemed “undruggable.”
Alnylam cofounder and Nobel Laureate Dr. Phillip Sharp first published a paper on using RNA interference and double-stranded RNA to silence genes in mammalian cells in Genes & Development in 1999. This paper would prove to be the catalyst for the collaboration between Alnylam’s five founders that would ultimately lead to the creation of the company in 2002.READ THE PAPER › READ THE PAPER ›
Performing the earliest and foundational research into how to utilize RNAi to silence genes that cause disease, Alnylam pioneered the first phase of the RNAi Revolution. Through sustained research and development efforts over more than 15 years, our work yielded the critical breakthroughs and innovations that made the field of RNAi therapeutics possible.
The Wall Street Journal article
Published: August 10, 2018
*Licensed to Novartis